TRK Inhibitors: A Tumor Agnostic Approach to Treatment of Solid Tumors

The FDA has given the novel agent NVL-655 a breakthrough therapy designation for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Findings from a phase 1b/2 study support the continued development of palazestrant plus ribociclib for patients with estrogen receptor-positive/HER2-negative metastatic breast cancer.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.

The phase 2 VERSATILE-002 trial evaluating Versamune HPV with pembrolizumab met its primary end point in patients with first-line recurrent metastatic head and neck squamous cell cancer.